期刊文献+

TEA方案治疗急性髓系白血病21例

原文传递
导出
摘要 目的 观察以拓扑替康(TPT)、依托泊苷(VP16)、阿糖胞苷(Ara-C)为主的TEA方案治疗急性髓系白血病(AML)的疗效.方法 采用TEA方案治疗21例AML患者每天TPT 1.5 mg/m2,第1天至第3天,VP16每天150 mg/m2,第4天至第6天,Ara-C每天100~200 mg/m2,第1天至第7天,均静脉滴注.结果 21例患者中完全缓解(CR)13例(61.9%),部分缓解(PR)2例(9.6%),总有效率71.5%,未缓解(NR)6例(28.5%).结论 TEA方案是治疗AML的有效方案.
出处 《白血病.淋巴瘤》 CAS 2008年第2期-,共2页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献5

  • 1张之南.血液病诊断及疗效标准[S]北京:科学出版社,1998228-236349-360385-387396-401.
  • 2Bonnet JA,Kozelsky TF. The significance of the sequence of administration of topotecan and etoposide[J].Cancer Chemotherapy and Pharmacology,1996,(1-2):109-112.doi:10.1007/s002800050545.
  • 3Cooper BW,Donaher E,Lazarus HM. A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients With relapsed or refractory acute myelogenous and lymphoblastic leukemia[J].Leuk Bes,2003,(01):35-44.
  • 4Mainwaring MG,Rimsza LM,Chen SF. Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide +Mitoxantrone (T-EM) and correlation with topoisomerase Ⅱ levels[J].Leukemia and Lymphoma,2002,(05):989-999.doi:10.1080/10428190290021339.
  • 5Norgaard JM,Olesen LH,Olesen G. FAB M4 and high CD14surface expression is associated with high cellular resistance to Ara-C and daunorubicin:implications for clinical outcome in acute myeloid leukemia[J].Eur J Hacmatol,2001,(04):221-229.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部